This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.

Page 38





• UK-originated medicines account for 16 per cent of the sales of the world’s top 100 drugs, second only to the US.

• The UK has created five of the world’s top 20 best-selling medicines and has discovered as many leading medicines as the rest of Europe combined.

• The UK produces the highest number of life sciences graduates annually in Western Europe.

• The UK has the largest biopharmaceutical pipeline in the EU, with 31 per cent of biopharmaceuticals in development originating here.

• The UK life sciences industry spends almost £5bn on research and development (R&D) annually.

• The UK attracts almost 10 per cent of the world’s pharmaceutical R&D funding.

• Two of the top five global pharmaceutical companies have their headquarters in the UK.

• Thir ty five per cent of European biopharmaceutical trials take place in the UK.

• On average, the NHS serves one million patients every 36 hours, which is equivalent to eight patients every second.

• Over the last decade, life sciences departments within UK universities have generated more than 200 spin-out companies, employing in excess of 1,000 people.



(...Continued from page 37) collectively together to develop and deliver pioneering ideas.


Opportunities are particularly ripe in the NHS. One of the largest purchasers of life sciences products in the world, it spends around £15bn each year on goods and services and supports a wide range of innovative technologies.


Recent overseas investors into the NHS include Partec, a German manufacturer of diagnostic products aimed at detecting HIV, malaria and tuberculosis, which established a UK office in Kent in 2007. The company, which set up its Canterbury-based facility with the help of UK Trade & Investment, now sells its products into pathology laboratories within NHS hospitals and specialist clinics. Jane Wood, chief operating officer of Partec UK Ltd, said: “The NHS is the largest single healthcare delivery organisation in the world and as such is of vital importance to our company from a financial and moral viewpoint.


“Traditionally, the UK was served from our German HQ, but in the last few years it has become obvious that having someone on the ground is crucial to fast track sales growth here.”




Life sciences businesses that are based in the UK also fl ourish because of the country’s world-class commercial infrastructure.


The recognised gateway to Europe, the UK is consistently ranked as having one of the best business environments in the world and has a globally admired regulatory regime, with two internationally recognised product approval agencies being UK-based. It also has a pro-science investment climate, as illustrated by the recent establishment of the UK Innovation Investment Fund, which at its first closing attracted £325m. Commenting on such support, Mark W J Ferguson, CEO of biopharmaceutical product firm Renovo, says: “The UK offers us exactly what we are looking for in developing our business.”




Looking ahead, the future looks exceptionally bright for the UK life sciences industry. The country is committed to continuing its backing of highly innovative activity in the sector, with the Government allocating resource spending of £4.6bn a year to scientific research by 2014-15. Moreover the work of the Office for Life Sciences continues, supported in particular by close working between officials from the Department for Business, Innovation and Skills and the Department of Health. Work aims to improve the UK operating environment for life sciences companies and is focussed in areas including improving (Continued on page 39...)



springboard: | page 38

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52